Vanda Pharmaceuticals (VNDA) Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for VNDA from our risk checks.
VNDA Community Fair Values
Create NarrativeSee what 21 others think this stock is worth. Follow their fair value or set your own to get alerts.
Vanda Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.35 |
| 52 Week High | US$5.70 |
| 52 Week Low | US$3.81 |
| Beta | 0.74 |
| 1 Month Change | -14.71% |
| 3 Month Change | 3.82% |
| 1 Year Change | -6.65% |
| 3 Year Change | -58.69% |
| 5 Year Change | -62.90% |
| Change since IPO | -55.06% |
Recent News & Updates
Recent updates
Vanda: Next Phase Of Fanapt Growth Might Be With Bysanti Advancement
Aug 29
New Indications And Pipeline Advances Will Strengthen Position
Expansion of Fanapt's sales and marketing efforts is expected to drive significant revenue growth through increased brand awareness and prescriber engagement.Vanda's Struggles Persist Despite New Drug Launches And Takeover Bids
Sep 05Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over
Aug 08Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest
Jun 18Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much
Apr 05Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Feb 15
Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash
Feb 13Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement
Feb 10News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts
Nov 11Shareholder Returns
| VNDA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -20.9% | 3.1% | 0.5% |
| 1Y | -6.7% | 3.9% | 20.0% |
Return vs Industry: VNDA underperformed the US Biotechs industry which returned 5.5% over the past year.
Return vs Market: VNDA underperformed the US Market which returned 19.8% over the past year.
Price Volatility
| VNDA volatility | |
|---|---|
| VNDA Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VNDA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VNDA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 368 | Mihael Polymeropoulos | www.vandapharma.com |
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis.
Vanda Pharmaceuticals Inc. Fundamentals Summary
| VNDA fundamental statistics | |
|---|---|
| Market cap | US$255.27m |
| Earnings (TTM) | -US$84.20m |
| Revenue (TTM) | US$212.07m |
Is VNDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VNDA income statement (TTM) | |
|---|---|
| Revenue | US$212.07m |
| Cost of Revenue | US$11.80m |
| Gross Profit | US$200.27m |
| Other Expenses | US$284.47m |
| Earnings | -US$84.20m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.42 |
| Gross Margin | 94.44% |
| Net Profit Margin | -39.70% |
| Debt/Equity Ratio | 0% |
How did VNDA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/31 05:37 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vanda Pharmaceuticals Inc. is covered by 15 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Argus Research Company |
| Olivia Brayer | BofA Global Research |
| Corey Davis | Canaccord Genuity |